200 related articles for article (PubMed ID: 35423994)
1. Tailoring amphotericin B as an ionic liquid: an upfront strategy to potentiate the biological activity of antifungal drugs.
Hartmann DO; Shimizu K; Rothkegel M; Petkovic M; Ferraz R; Petrovski Ž; Branco LC; Canongia Lopes JN; Silva Pereira C
RSC Adv; 2021 Apr; 11(24):14441-14452. PubMed ID: 35423994
[No Abstract] [Full Text] [Related]
2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
3. [Antifungal macrocycle antibiotic amphotericin B - its present and future. Multidisciplinary perspective for the use in the medical practice].
Baghirova AA; Kasumov KM
Biomed Khim; 2021 Jul; 67(4):311-322. PubMed ID: 34414889
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.
Bellmann R
Curr Pharm Des; 2013; 19(20):3629-47. PubMed ID: 23278532
[TBL] [Abstract][Full Text] [Related]
6. Antifungal Macrocycle Antibiotic Amphotericin B-Its Present and Future. Multidisciplinary Perspective for the Use in the Medical Practice.
Baghirova AA; Kasumov KM
Biochem Mosc Suppl B Biomed Chem; 2022; 16(1):1-12. PubMed ID: 35194486
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
[TBL] [Abstract][Full Text] [Related]
8. [Liposomal amphotericin B].
Fukasawa M
Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):229-31. PubMed ID: 16282964
[TBL] [Abstract][Full Text] [Related]
9. Modulation of amphotericin B membrane interaction by cholesterol and ergosterol--a molecular dynamics study.
Czub J; Baginski M
J Phys Chem B; 2006 Aug; 110(33):16743-53. PubMed ID: 16913814
[TBL] [Abstract][Full Text] [Related]
10. Permeability Characteristics of a New Antifungal Topical Amphotericin B Formulation with γ-Cyclodextrins.
López-Castillo C; Rodríguez-Fernández C; Córdoba M; Torrado JJ
Molecules; 2018 Dec; 23(12):. PubMed ID: 30567325
[TBL] [Abstract][Full Text] [Related]
11. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
Viscoli C; Castagnola E
Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
[TBL] [Abstract][Full Text] [Related]
12. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.
Cavassin FB; Baú-Carneiro JL; Vilas-Boas RR; Queiroz-Telles F
Infect Dis Ther; 2021 Mar; 10(1):115-147. PubMed ID: 33523419
[TBL] [Abstract][Full Text] [Related]
13. Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium.
Böhme A; Karthaus M
Chemotherapy; 1999; 45(5):315-24. PubMed ID: 10473919
[TBL] [Abstract][Full Text] [Related]
14. Interaction of amphotericin B and saturated or unsaturated phospholipid monolayers containing cholesterol or ergosterol at the air-water interface.
Wang J; Ma Y; Hou S; Miao Z; Ma Q
Biophys Chem; 2020 Mar; 258():106317. PubMed ID: 31918025
[TBL] [Abstract][Full Text] [Related]
15. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.
Castagnola E; Bucci B; Montinaro E; Viscoli C
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():97-106. PubMed ID: 8932808
[TBL] [Abstract][Full Text] [Related]
16. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
17. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
18. Safe and Effective Delivery of Amphotericin B: A Survey of Patents.
Kaur L; Abhijeet ; Jain SK
Recent Pat Nanotechnol; 2017; 11(3):214-234. PubMed ID: 28056751
[TBL] [Abstract][Full Text] [Related]
19. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
20. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
